Journal of Preventive Medicine

To Assess the Efficacy Outcomes of Patients Undergoing Androgen Deprivation Therapy in a Tertiary Care Hospital: A Retrospective Study

Prostate cancer has become a big concern globally, with over one million cases diagnosed each year and over 300,000 fatalities, making it the sixth highest cause of cancer death in males. Androgen Deprivation Therapy (ADT) is one of the most often used treatments for prostate cancer; thus, determining its safety and efficacy is critical. The study's goal was to evaluate the efficacy of androgen deprivation therapy in prostate cancer patients. From 2013 to 2019, patients having radiation therapy and receiving ADT were studied in this single-center, retrospective, observational study in a tertiary care hospital in Southern Kerala with frequent follow-up for one year. Medical records were used to gain patient data for the analysis and then entered into a data collection form. The study enrolled a total of 140 participants. The results reveal that the mean of the initial PSA (Prostate-Specific Antigen) values obtained was 43.06 and that after three months, the mean value of PSA was 6.16, six months, 2.53, one year, 2.21, and finally, two years, the mean value of PSA was 0.49. The study shows a reduction in PSA values progression in the patients undergoing androgen deprivation therapy. Patients who took ADT had their PSA values decrease in progression, and the benefit of ADT was shown to be best when treated earlier.

Author(s): Eldhose Elias George, Anjali Ambrose, Dr. Shaji George and Dr. Judith Aaron

Abstract | Full-Text | PDF

Share this